Walter Public Investments Inc. Buys New Shares in Eli Lilly and Company $LLY

Walter Public Investments Inc. bought a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,900 shares of the company’s stock, valued at approximately $9,141,000. Eli Lilly and Company makes up approximately 2.2% of Walter Public Investments Inc.’s investment portfolio, making the stock its 20th biggest position.

A number of other hedge funds have also added to or reduced their stakes in the business. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. Jupiter Topco LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $4,667,180,000. Corient Private Wealth LP acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $764,116,000. BlackRock Inc. boosted its stake in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. Finally, State Street Corp boosted its stake in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on LLY shares. Scotiabank raised their price target on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Argus increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a research report on Tuesday, September 15th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,437.46 on Thursday. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00. The stock’s 50 day moving average is $1,231.13 and its 200-day moving average is $1,106.42. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $1.35 trillion, a price-to-earnings ratio of 46.66, a PEG ratio of 1.72 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the firm posted $7.02 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 35.67 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Recent Eli Lilly and Company Headlines

Investors following LLY have been watching these headlines:

• Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add a warning about rare NAION-related vision loss. Zepbound is among the medicines affected, creating a potential safety concern for Lilly’s key product category. Article: FDA warning on GLP-1 drugs
• Negative Sentiment: Possible new U.S. drug-price negotiations could put pressure on Lilly revenue, according to a report identifying the company as facing nearer-term pricing exposure. Article: Drug-pricing risks

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.